

## Effective Contraceptive Use

### Measure Basic Information

**Name and date of specifications used:** OHA is developing these specifications based on national specifications under development with the Centers for Disease Control and Prevention (CDC) and the Centers for Medicare and Medicaid Services (CMS), and in collaboration with the Oregon Preventive Reproductive Health Advisory Council and the Metrics Technical Advisory Workgroup.

These specifications are still in draft form: they will be finalized and posted online in December.

**URL of Specifications:** n/a

**Measure Type:**

HEDIS  PQI  Survey  Other  Specify: OHA-developed

**Measure Utility:**

CCO Incentive  Core Performance  CMS Adult Set  CHIPRA Set  State Performance   
Other  Specify:

**Data Source:** MMIS/DSSURS

**Measurement Period:** January 1, 2015 - December 31, 2015.

**2015 Benchmark:** 50%. Metrics & Scoring Committee consensus.

**Denied claims:** Included  Not included

### Measure Details

**Data elements required denominator:** All women ages 15-50 as of December 31 of the measurement year who were continuously enrolled in a CCO for the 12-month measurement period.

Note: OHA will be measuring and reporting on adolescent and adult women separately, by ages 15-17 and ages 18-50. Only the adult rate will be tied to the CCO's incentive payment.

**Required exclusions for denominator:**

Step 1) Remove from the denominator any women with evidence of the following:

Exclusion	Diagnosis Codes	CPT	HCPCS
Hysterectomy	V88.01		
Bilateral oophorectomy	V65.5x	58720, 58150, 58940, 58700	

Exclusion	Diagnosis Codes	CPT	HCPCS
Natural Menopause	V49.81, 627.0-627.9		
Premature menopause due to survey, radiation, or other factors	V256.2, 256.31		

**Data elements required numerator:**

Women in the denominator with evidence of one of the following methods of contraception during the measurement period: sterilization, IUD, implant, contraception injection, contraceptive pills, patch, ring, or diaphragm using the codes below.

Note: the measure is only looking for codes during the measurement period; no look back periods are applied. However, a number of surveillance codes are included in the specifications to account for women utilizing long-acting reversible contraception or permanent contraceptive options who would not otherwise have a pharmacy claim or procedure code during the 12-month measurement period.

Note: the surveillance and diagnosis codes listed below do not need to be primary diagnoses; they can be in any position on the claim for credit toward this measure.

Note: use of any of the codes below “count” independently; codes do not have to be used in combination (e.g., CPT and NDC) for inclusion in the numerator.

Note: all NDC codes have been temporarily removed from the draft specifications, pending OHA’s review and revision with CMS /CDC. They will be re-instated in the final version of the specs.

Description	ICD-9	CPT	HCPCS	NDC codes
Surveillance of a contraceptive method  Surveillance codes are necessary because of long-acting methods like sterilization and IUDs/ implants.  <b>Surveillance codes for unspecified contraceptive methods are under review (marked with asterisks).</b>	<p><b>V25.4</b>, Surveillance of previously prescribed contraceptive methods*</p> <p><b>V25.40</b>, Contraceptive surveillance, unspecified*</p> <p><b>V25.41</b>, Surveillance of oral contraceptive.</p> <p><b>V25.42</b>, Surveillance of previously prescribed contraceptive method, intrauterine device.</p> <p><b>V25.43</b>, Surveillance of</p>			

Description	ICD-9	CPT	HCPCS	NDC codes
	<p>previously prescribed contraceptive method; implantable sub-dermal contraceptive.</p> <p><b>V25.49</b>, Surveillance of other contraceptive method*</p> <p><b>V25.9</b>, Unspecified contraceptive management*</p> <p><b>V45.59</b> Presence of other contraceptive device</p>			
Female Sterilization	<p><b>V25.2</b>, Sterilization</p> <p><b>V26.51</b>, Tubal ligation status</p> <p><b>66.2x</b>, Bilateral endoscopic destruction or occlusion of fallopian tubes</p>	<p><b>58565, 58600, 58605, 58615, 58611, 58670, 58671, 58340, 74740</b></p>	<p><b>A4264, 58340, 74740</b></p>	
Intrauterine device (IUD/IUS)	<p><b>V25.11</b>, Encounter for insertion of intrauterine contraceptive device.</p> <p><b>V25.13</b>, Encounter for removal and reinsertion of intrauterine contraceptive device.</p> <p><b>V25.42</b>, Surveillance of previously prescribed contraceptive method, intrauterine device.</p> <p><b>V45.51</b>, Post-surgical presence of intrauterine contraceptive device.</p> <p><b>69.7</b>, Insertion of intrauterine contraceptive</p>	<p><b>58300</b>, Insertion of IUD</p>	<p><b>J7300</b>, Intrauterine copper contraceptive</p> <p><b>J7302</b>, Levonorgestrel-releasing intrauterine contraceptive system, 52 mg</p> <p><b>S4989</b>, Contraceptive intrauterine device (e.g. progestacertiud), including implants and supplies</p>	

Description	ICD-9	CPT	HCPCS	NDC codes
	<p>device.</p> <p><b>996.32</b>, Mechanical complication due to intrauterine contraceptive device or infection.</p> <p><b>996.65</b>, Infection and inflammatory reaction due to other genitourinary device, implant, and graft.</p>		<p><b>Q0090</b>, Skyla (2013)</p> <p><b>S4981</b>, Insertion of levonorgestrel-releasing intrauterine system</p>	
Hormonal implant	<p><b>V25.5</b>, Encounter for contraceptive management, insertion of implantable subdermal contraceptive,</p> <p><b>V25.43</b>, Surveillance of previously prescribed contraceptive method; implantable subdermal contraceptive.</p> <p><b>V45.52</b>, Post-surgical presence of subdermal contraceptive implant.</p> <p><b>996.30</b>, Mechanical complication of unspecified genitourinary device, implant, and graft.</p>	<p><b>11981</b>, Insertion, non-biodegradable drug delivery implant, Implanon or Nexplanon</p> <p><b>11983</b>, Removal with reinsertion, non-biodegradable drug delivery implant, Implanon or Nexplanon</p>	<p><b>J7306</b>, Levonorgestrel (contraceptive) implant system, including implants and supplies</p> <p><b>J7307</b>, Etonogestrel [contraceptive] implant system, including implant and supplies</p> <p>(A4260, Levonorgestrel implant system, code expired 2006</p> <p>S0180, Etonogestrel implant system, code expired 2008)</p>	
Injectable (1-month/3-month)	<b>V25.9</b> , Unspecified contraceptive management*	<p><b>96372</b>, injection</p> <p><b>90772</b>, before 2009</p>	<p><b>J1050, 1051, 1055, 1056</b>, Injection, medroxyprogesterone acetate, 1</p>	<b>[NDC codes pending review]</b>

Description	ICD-9	CPT	HCPCS	NDC codes
			mg  (J1051, Injection, medroxyprogesterone acetate, 50 mg, code expired 2013  J1055, Injection, medroxyprogesterone acetate for contraceptive use, 150 mg, code expired 2013  J1056, Injection, medroxyprogesterone acetate / estradiol cypionate, 5mg / 25mg, code expired 2013)	
Oral contraceptive	<b>V25.01</b> , Counseling and prescription of oral contraceptives.  <b>V25.41</b> , Surveillance of oral contraceptive.  <b>V25.9</b> , Unspecified contraceptive management*		<b>S4993</b> , Contraceptive pills for birth control	[NDC codes pending review]
Patch	<b>V25.9</b> , Unspecified contraceptive management*  <b>V25.40</b> , Contraceptive surveillance, unspecified*		<b>J7304</b> , Contraceptive supply, hormone containing patch, each	[NDC codes pending review]
Vaginal ring	<b>V25.9</b> , Unspecified contraceptive management*		<b>J7303</b> , Contraceptive supply, hormone containing	[NDC codes pending review]

Description	ICD-9	CPT	HCPCS	NDC codes
	<b>V25.40</b> , Contraceptive surveillance, unspecified*		vaginal ring, each	
Diaphragm	<b>V25.02</b> , initiation of other contraceptive measures, fitting of diaphragm	<b>57170</b>	<b>A4266</b> , Diaphragm for contraceptive use	

**Required exclusions for numerator:**

Among women in the denominator who were *not* numerator compliant, exclude those with a pregnancy diagnosis from the measure.

Diagnosis	CPT
V22.x, v61.7, v72.42	59400, 59409, 59410, 59510, 59514, 59515, 59610, 59612, 59614, 59618, 59620, 59622, 59425, 59426

OHA is still exploring an expanded list of codes to identify women are pregnant or were pregnant during the measurement year, based on the Timeliness of Prenatal Care measure specifications.

**What are the continuous enrollment criteria:** the 12-month measurement period.

**What are allowable gaps in enrollment:** No more than one gap in enrollment of up to 45 days during the measurement period.

**Define Anchor Date (if applicable):**